Regulation Of Glucose Uptake By Tropomyosins And Myosins
Funder
National Health and Medical Research Council
Funding Amount
$609,320.00
Summary
Defective import of glucose from the blood into fat and muscle is a key cause of adult-onset diabetes. We have identified a novel mechanical structure within muscle and fat cells defined by the protein tropomyosin that is involved in glucose import and potentially provides new targets for treatment of adult-onset diabetes and obesity.
Role Of AMPK Signaling In Metabolic Control During Exercise
Funder
National Health and Medical Research Council
Funding Amount
$566,288.00
Summary
It is well recognized that sedentary life styles are associated with increased incidence of obesity, Type 2 diabetes and atherosclerotic cardiovascular disease. The medical, social and financial costs of these diseases are growing rapidly and represent a major health care challenge. Exercise is beneficial for maintaining health in patients at risk of developing these diseases and for this reason we are interested in understanding how exercise capacity is regulated.
Dissecting The Role Of Insulin-regulated Phosphorylation Of Rab Guanine Nucleotide Exchange Factors In GLUT4 Trafficking
Funder
National Health and Medical Research Council
Funding Amount
$628,459.00
Summary
Diabetes and obesity are epidemic in the developed world. Impaired insulin action is a major cause. A key contributor is reduced glucose uptake into muscle and fat driving the pancreas to overproduce insulin. We have recently discovered three new molecules that we believe hold the secret to how insulin regulates the removal of the glucose from the blood stream after a meal. This proposal focuses on these three molecules and their regulation.
Targeting Skeletal MTORC1 As A Novel Approach For The Treatment Of Diet-induced Insulin Resistance
Funder
National Health and Medical Research Council
Funding Amount
$586,979.00
Summary
Diet-induced insulin resistance is a pathology that underlies type 2 diabetes. Elucidating the pathways and tissues that contribute to this condition is crucial for drug development. The skeleton has emerged as a critical insulin target tissue. We provide evidence that suppression of mTORC1, a complex over-activated by nutrients, in bone cells improves insulin sensitivity. In this study, we will determine if blocking mTORC1 function in bone cells can treat diet-induced insulin resistance.
A Novel Portable System For Day And Night Closed Loop Automated Insulin Delivery In The Patient With Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$251,133.00
Summary
For patients with Type 1 Diabetes, improved glucose control has been shown to reduce the development of diabetes complications. Although advances have been made in therapy, most people with diabetes do not achieve optimal treatment targets and the burden of care is high. Technologies now exist that allow the development of automatic insulin therapy and the artificial pancreas. These experiments will test a novel portable system that represents a significant step advancing toward this goal.
Epilepsy is often poorly controlled by medication and dietary measures can be taken that reduce occurrence of epileptic seizures. Glucose control is impacted by diet and also mutations in the genes that move glucose around the body are known to cause epilepsy. Here we will be studying how the genetic and dietary control of glucose levels impacts brain function to increase seizures and to potentially reveal novel therapies.
Carnitine Acetyltransferase (CrAT) Regulates Appetite And Body Weight Through The Melanocortin System
Funder
National Health and Medical Research Council
Funding Amount
$547,087.00
Summary
Carnitine metabolism in peripheral tissues, such as muscle, maintains appropriate cellular metabolism and function. Little is known about carnitine metabolism in specific populations of brain cells regulate food intake and appetite. This project aims to understand how carnitine metabolism affect brain cells that regulate food intake and body weight.
Glycaemia-increasing Effects Of Sprinting In Type 1 Diabetes: Toward The Validation Of New Clinical Guidelines For Hypoglycaemia Prevention
Funder
National Health and Medical Research Council
Funding Amount
$600,323.00
Summary
Recently, we found that the risk of hypoglycaemia associated with moderate intensity exercise in type 1 diabetic individuals is opposed by one or several short sprints performed during or after exercise. Our goal is to examine if exercising several hours before sprinting decreases its protective effect, and whether sprinting may impair several hours later the counterregulatory responses to hypoglycaemia. Finally, we will determine if guidelines advocating the use of short sprints reduce the risk ....Recently, we found that the risk of hypoglycaemia associated with moderate intensity exercise in type 1 diabetic individuals is opposed by one or several short sprints performed during or after exercise. Our goal is to examine if exercising several hours before sprinting decreases its protective effect, and whether sprinting may impair several hours later the counterregulatory responses to hypoglycaemia. Finally, we will determine if guidelines advocating the use of short sprints reduce the risk of hypoglycaemia under free living conditions.Read moreRead less
Type 2 diabetes is a health crisis in Australia. In this project, we will investigate the mechanisms whereby high glucose and fat impair pancreatic beta-cell function leading to type 2 diabetes. We will establish how endoplasmic reticulum stress and the protein Id1 are linked with loss of beta-cell gene expression and function. The information gained will further our understanding of the basic mechanisms regulating insulin secretion and provide new therapeutic targets for diabetes treatment.
Post-stroke Hyperglycaemia – Treatment With Exenatide In Acute Ischaemic Stroke (TEXAIS) Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,266,149.00
Summary
Raised blood glucose levels (hyperglycaemia) after a stroke is common. It reduces the efficacy of stroke treatments and results in worse outcomes. Insulin is not useful as a treatment for this as it causes frequent hypoglycaemia and does not improve clinical outcomes. Exenatide is a common diabetes drug that is simple to use and lowers blood glucose without hypoglycaemia. It will be tested in the Treatment with Exenatide in Acute Ischaemic Stroke (TEXAIS) trial.